Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD38/CS1 Dual-Target CAR-T in Relapsed/Refractory Multiple Myeloma
NCT06574958Phase 1Active, not recruiting
- Sponsor
- Second Hospital of Shandong University
- Start
- Apr 2024
- Primary completion
- Jan 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cd38 chimeric antigen receptor t cells + cs1 chimeric antigen receptor t cells in multiple myeloma (MM), sponsored by Second Hospital of Shandong University. Primary endpoint: Objective Response Rate at 1 year. Started Apr 2024; status: active, not recruiting.
02
Drugs
cd38 chimeric antigen receptor t cells + cs1 chimeric antigen receptor t cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06574958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06574958.